Genmab A/S
CSE:GMAB
Genmab A/S
Net Issuance of Common Stock
Genmab A/S
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Net Issuance of Common Stock
-kr3.8B
|
CAGR 3-Years
-129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Issuance of Common Stock
kr8.2B
|
CAGR 3-Years
122%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Issuance of Common Stock
€340.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
22%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Issuance of Common Stock
kr99.3m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
77%
|
CAGR 10-Years
-9%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Net Issuance of Common Stock
kr81.4m
|
CAGR 3-Years
165%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Net Issuance of Common Stock
kr88.9m
|
CAGR 3-Years
552%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
-3.8B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Net Issuance of Common Stock amounts to -3.8B DKK.
What is Genmab A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
-129%
Over the last year, the Net Issuance of Common Stock growth was -810%. The average annual Net Issuance of Common Stock growth rates for Genmab A/S have been -129% over the past three years .
You don't have any saved screeners yet